share_log

Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

Benzinga ·  May 8 06:03

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment